South Africa has the highest obesity prevalence in sub-Saharan Africa. Nearly half of all adults are overweight or obese. Among women, the numbers are even more striking — approximately 68% are classified as overweight or obese, with the prevalence among women of reproductive age rising from 51% to 60% over the past three decades.

These aren't abstract statistics. They translate directly into rising rates of type 2 diabetes, cardiovascular disease, hypertension, and certain cancers. Researchers at the University of the Witwatersrand have noted that weight-related diseases have now overtaken tuberculosis and HIV as leading causes of illness and death in the country.

And yet, South Africa's healthcare system still treats obesity as something closer to a lifestyle inconvenience than the chronic medical condition it is.

Why Obesity Isn't Simply a Choice

The public conversation around weight in South Africa — and globally — has long been dominated by a simple narrative: eat less, move more. If you're overweight, the implication goes, you're making bad choices.

The science tells a fundamentally different story. Obesity is a complex, chronic condition driven by the interaction of genetics, hormones, environment, socioeconomic factors, and neurological pathways. The hormones that regulate hunger and satiety — including GLP-1, ghrelin, and leptin — function differently in people with obesity, creating biological drives that are far more powerful than willpower alone.

South Africa's particular context adds further complexity. The country is undergoing what researchers call a "nutrition transition" — a shift from traditional diets toward highly processed, calorie-dense foods driven by urbanisation and the economics of food access. Many South Africans face a paradox: food insecurity and obesity coexist in the same households, because the cheapest and most accessible foods tend to be the most calorically dense and nutritionally poor.

Cultural factors also play a role. Research conducted in several provinces has found that in some communities, a larger body size is associated with health, prosperity, and happiness — while thinness can carry stigma, partly due to its association with HIV/AIDS. These perceptions, while understandable in context, can delay help-seeking behaviour and make it harder to frame obesity as a medical concern rather than an aesthetic preference.

The Health Consequences Are Severe

Obesity is a primary risk factor for many of South Africa's most burdensome diseases:

Type 2 diabetes is closely linked to excess weight, and South Africa has over four million people living with diabetes. GLP-1 medications were originally developed specifically for this condition.

Cardiovascular disease — including heart attacks, strokes, and hypertension — is strongly associated with obesity. These are now among the leading causes of death in the country.

Certain cancers — including breast, colorectal, and endometrial cancers — have established links to excess body fat.

Mental health conditions — depression, anxiety, and reduced quality of life are significantly more common in people living with obesity, compounded by social stigma and the psychological burden of repeated failed weight loss attempts.

Musculoskeletal problems — osteoarthritis and chronic pain conditions are more prevalent and more severe in people carrying excess weight.

The economic burden is enormous too. Obesity-related healthcare costs strain both the public and private health systems, and lost productivity from obesity-associated chronic disease has a measurable impact on the economy.

Why the Healthcare System Is Falling Short

Despite the scale of the problem, South Africa's healthcare response to obesity remains inadequate in several key ways.

Obesity is not a prescribed minimum benefit. Medical schemes are required to cover diabetes treatment, but not obesity itself. This means the very condition that drives many cases of diabetes — excess weight — isn't funded for treatment. It's like covering the cost of a broken bone but refusing to fund the fall prevention programme.

GLP-1 medications are too expensive for most. At R3,000 to R6,000 per month, GLP-1 treatments are out of reach for the majority of South Africans. They're not available in the public health sector at all, and private sector access is limited to those who can pay out of pocket.

There's no national obesity strategy with teeth. While SAMMSS published clinical practice guidelines in November 2025 recommending GLP-1s for obesity treatment, and the National Department of Health has a strategic plan for non-communicable diseases, comprehensive implementation remains limited.

Stigma within healthcare itself. Many patients report feeling judged or dismissed by healthcare providers when raising weight concerns. This discourages people from seeking treatment and perpetuates the idea that obesity is a personal failing rather than a medical condition.

What's Changing

There are reasons for measured optimism.

The global medical consensus is shifting rapidly. The World Health Organisation is developing guidelines for the use of GLP-1 agonists in obesity treatment, expected in mid-2025, and is considering adding these medications to its Essential Medicines List. If adopted, this would put significant pressure on national health systems — including South Africa's — to improve access.

SAMMSS guidelines now formally recognise GLP-1 medications as part of the treatment toolkit for obesity, alongside dietary intervention, physical activity, behavioural therapy, and bariatric surgery. This is an important step in legitimising pharmacological treatment for weight management in the South African clinical context.

Generic competition is on the horizon. Key patents on semaglutide are expiring in multiple countries, and Aspen Pharmacare has announced plans to manufacture and distribute generic versions. Analysts project these could reach South Africa by 2027, potentially cutting costs dramatically and bringing these treatments within reach of a much larger population.

Telehealth is improving access. Doctor-supervised GLP-1 treatment delivered remotely removes several barriers — geographic distance, cost of specialist visits, scheduling constraints, and the stigma some patients feel about discussing weight in person. It's not a complete solution, but it's a meaningful step toward making evidence-based treatment available to more people.

What Needs to Happen

Addressing South Africa's obesity crisis requires action on multiple levels — and GLP-1 medications alone won't solve it. But they're a clinically proven intervention that, combined with lifestyle change, can meaningfully reduce the burden of obesity-related disease for millions of South Africans.

What's needed is a healthcare framework that recognises obesity as the chronic medical condition it is. That means PMB classification, funded treatment pathways, affordable medication, and destigmatised access to professional help.

Until the system catches up, individuals who can access treatment should do so through legitimate, doctor-supervised channels — and should approach it not as a cosmetic fix but as a serious medical intervention with real health benefits.